PD-089828

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NamePD-089828
Drug Alias NamePD-089828
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsTyrosine-protein kinase SRC inhibitorsFibroblast growth factor receptor 1 inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1Platelet-derived growth factor receptor betaFibroblast growth factor receptor 1 +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesParke-Davis GmbhPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesParke-Davis Gmbh
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A